Spero Therapeutics is trading 6.72% up at $1.27 after its August 12, 2026 earnings release highlighted FDA-approved Utebzi and a $105 million non-dilutive royalty financing.

  • Second-quarter revenue was zero, while net loss reached $9.6 million; adjusted EPS of -$0.16 beat the expected -$0.17.
  • The immunology-focused SP001 strategy was also highlighted, and financing extends the cash runway into the second half of 2029.